Tag archive for ‘AB rated generic to Byetta’
Antares Pharma: This Small, Emerging Biotechnology Company Is Poised for Explosive Growth Based on Five Major New Product Introductions by 2020 (ATRS, Buy, $3.02
Investment Thesis Antares is one of my top recommendations based on its extremely impressive pipeline prospects. In a March 23, 2017 report Antares: Pipeline is Bursting with Late Stage Products (ATRS, $2.77, Buy) I did an in-depth analysis that goes over my assumptions and resultant projections in great detail for the five partnered products and two […]
Antares: Some Key Points from 3Q, 2016 Conference Call (ATRS, Buy, $1.84)
Investment Opinion In my opinion, Antares is substantially undervalued. My price target is $6 60 in 2018. The thinking behind this was explained in my April 22, 2016 report “An Outstanding Product Pipeline Promises Dramatic Growth Through 2022” (see this link) If you are unfamiliar with the Company or need to be refreshed, I would suggest […]
Antares: Undeterred by the Poor Stock Performance I Continue to Pound the Table (ATRS. Buy, $1.30)
Upcoming Catalysts This is a detailed note updating my thinking on Antares and discussing how I come up with my 2017 price target range of $3.25 to $10.00; the latter is based on Antares being acquired (probably by Teva). Additionally, I wanted to make you aware of three catalysts that could bolster investors’ confidence. There […]